Table 4.
All patients n = 119 | Non-AKI n = 68 | Mild AKI n = 17 | Severe AKI n = 34 | |
---|---|---|---|---|
ACEI or ARB, n (%) | 6 (5) | 4 (5.9) | 2 (11.8) | 0 |
Antibiotics, n (%) | 110 (92.4) | 62 (91.2) | 16 (94.1) | 32 (94.1) |
Antivirus, n (%) | 88 (73.9) | 51 (75) | 13 (76.5) | 24 (70.6) |
Antidiabetic, n (%) | 41 (34.5) | 19 (27.9) | 6 (35.3) | 16 (47.1) |
Diuretic, n (%) | 78 (65.5) | 38 (55.9) | 13 (76.5) | 27 (79.4) |
Glucocorticoid, n (%) | 89 (74.8) | 50 (73.5) | 10 (58.8) | 29 (85.3) |
AKI, acute kidney injury; COVID-19, coronavirus disease 2019; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker.